Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Le Kremlin-Bicetre – page 236

3 418 clinical trials in Le Kremlin-Bicetre, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Kremlin-Bicetre at a glance
3 418
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 418 trials in Le Kremlin-Bicetre

Open in trial search

Study on the Effectiveness and Safety of Alectinib, Entrectinib, and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Neoplasm

Not recruiting

Study of PRS-344/S095012 and obinutuzumab combination for patients with solid tumors - First human trial to evaluate safety and effectiveness

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Study on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lorlatinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Study of pirtobrutinib, venetoclax and rituximab combination compared to venetoclax and rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Transplant rejection

Not recruiting

Study on Riliprubart for Preventing and Treating Antibody-Mediated Rejection in Adult Kidney Transplant Patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Biogen Idec Research Limited

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Malignant melanoma+1

Not recruiting

Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Naporafenib
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Le Kremlin-Bicetre

What the registry says about research in the country

01 Bacterial Infections and Mycoses

Research in this area focuses on bacterial infections, especially severe ear, nose and throat diseases such as idiopathic purulent oedematous sinusitis in adults. The trials are aimed at evaluating whether treatment can improve symptoms and overall patient well-being.

  • Testing a treatment approach for persistent sinus infection
  • Assessing improvement in quality of life over time

In Kremlin Bicêtre, this work reflects a practical effort to better manage chronic ENT infection-related complaints.

02 Cardiovascular Diseases

Clinical research here also covers cardiovascular disease in patients hospitalized for septic shock with tachycardia and hypercontractility. The main goal is to evaluate whether controlling heart rate may help improve survival and clinical outcomes.

  • Studying a heart-rate-lowering strategy in septic shock
  • Comparing outcomes against standard care

These trials are designed to clarify whether better cardiovascular support can reduce risk in critically ill patients.

03 Otorhinolaryngologic Diseases

Another key research focus is otorhinolaryngology, with attention on sinusitis and related ENT disorders. The studies are looking at treatment effectiveness and changes in patient-reported symptoms during follow-up.

  • Measuring symptom relief in sinus disease
  • Tracking changes in disease-specific quality of life

This area highlights efforts to improve everyday functioning for patients living with ongoing nasal and sinus problems.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.